Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.

Fibroblast growth factor receptor 3 (FGFR3) mutations are frequently involved in human developmental disorders and cancer. Activation of FGFR3, through mutation or ligand stimulation, results in autophosphorylation of multiple tyrosine residues within the intracellular domain. To assess the importance of the six conserved tyrosine residues within the intracellular domain of FGFR3 for signaling, derivatives were constructed containing an N-terminal myristylation signal for plasma membrane localization and a point mutation (K650E) that confers constitutive kinase activation. A derivative containing all conserved tyrosine residues stimulates cellular transformation and activation of several FGFR3 signaling pathways. Substitution of all nonactivation loop tyrosine residues with phenylalanine rendered this FGFR3 construct inactive, despite the presence of the activating K650E mutation. Addition of a single tyrosine residue, Y724, restored its ability to stimulate cellular transformation, phosphatidylinositol 3-kinase activation, and phosphorylation of Shp2, MAPK, Stat1, and Stat3. These results demonstrate a critical role for Y724 in the activation of multiple signaling pathways by constitutively activated mutants of FGFR3.

[1]  Xin-Yuan Fu,et al.  Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism , 1997, Nature.

[2]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[3]  A. Kazlauskas,et al.  Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor beta subunit and are required for binding of phospholipase C gamma and a 64-kilodalton protein, respectively , 1993, Molecular and cellular biology.

[4]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[5]  Joseph Schlessinger,et al.  Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism , 1996, Cell.

[6]  Nanxin Li,et al.  Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis , 1992, Nature.

[7]  D. Levy,et al.  FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. , 1999, Genes & development.

[8]  W. Sellers,et al.  Apoptosis and cancer drug targeting. , 1999, The Journal of clinical investigation.

[9]  D. Donoghue,et al.  Activation of H-ras61L-specific signaling pathways does not require posttranslational processing of H-ras. , 2000, Experimental cell research.

[10]  M. Krasilnikov.  Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. , 2000, Biochemistry. Biokhimiia.

[11]  M. Jaye,et al.  A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1 , 1991, Molecular and cellular biology.

[12]  M. Moran,et al.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.

[13]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[14]  A. N. Meyer,et al.  Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 , 2000, Oncogene.

[15]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[16]  S. Decker.  Transmembrane signaling by epidermal growth factor receptors lacking autophosphorylation sites. , 1993, The Journal of biological chemistry.

[17]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[18]  B. Vandenbunder,et al.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering. , 1999, Molecular biology of the cell.

[19]  D. Donoghue,et al.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain , 1997, Molecular and cellular biology.

[20]  D. Donoghue,et al.  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.

[21]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Birnbaum,et al.  The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. , 1999, Blood.

[23]  D. Donoghue,et al.  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. , 1999, American journal of human genetics.

[24]  U. Hellman,et al.  Identification of two C‐terminal autophosphorylation sites in the PDGF beta‐receptor: involvement in the interaction with phospholipase C‐gamma. , 1992, The EMBO journal.

[25]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[26]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[27]  D. Donoghue,et al.  FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.

[28]  T. Sugimura,et al.  K-sam-related gene, N-sam, encodes fibroblast growth factor receptor and is expressed in T-lymphocytic tumors. , 1992, Cancer research.

[29]  J. Fallon,et al.  Fibroblast growth factors as multifunctional signaling factors. , 1999, International review of cytology.

[30]  C. Turck,et al.  Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways , 1992, Cell.

[31]  I. Lax,et al.  Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation , 1998, Molecular and Cellular Biology.

[32]  C. Deng,et al.  A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. , 1999, Human molecular genetics.

[33]  Jonathan A. Cooper,et al.  Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. , 1992, The EMBO journal.

[34]  R. Jove,et al.  Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. , 1998, Journal of biomedical science.

[35]  M. Jaye,et al.  Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction , 1996, Molecular and cellular biology.

[36]  M. Goldfarb,et al.  Novel Recognition Motif on Fibroblast Growth Factor Receptor Mediates Direct Association and Activation of SNT Adapter Proteins* , 1998, The Journal of Biological Chemistry.

[37]  Jonathan A. Cooper,et al.  GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor beta subunit , 1992, Molecular and cellular biology.

[38]  M. Mohammadi,et al.  Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. , 1999, Molecular biology of the cell.

[39]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[40]  J. Cooper,et al.  Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1. , 1993, Molecular biology of the cell.

[41]  R. Aguiar,et al.  Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. , 1998, Blood.

[42]  G. Guy,et al.  SHP2 associates directly with tyrosine phosphorylated p90 (SNT) protein in FGF-stimulated cells. , 1997, Biochemical and biophysical research communications.

[43]  M. Tremblay,et al.  Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356* , 1997, The Journal of Biological Chemistry.

[44]  K. Alitalo,et al.  Identification of Tek/Tie2 Binding Partners , 1999, The Journal of Biological Chemistry.

[45]  T L Blundell,et al.  Fibroblast growth factor receptors: lessons from the genes. , 1998, Trends in biochemical sciences.

[46]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Smedley,et al.  The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. , 1998, Human molecular genetics.

[48]  E. Liu,et al.  Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase , 1996, Molecular and cellular biology.

[49]  A. Kazlauskas,et al.  Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.

[50]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[51]  I. Lax,et al.  FRS2 Proteins Recruit Intracellular Signaling Pathways by Binding to Diverse Targets on Fibroblast Growth Factor and Nerve Growth Factor Receptors , 2000, Molecular and Cellular Biology.

[52]  A. Munnich,et al.  Fibroblast Growth Factor Receptor 3 Mutations Promote Apoptosis but Do Not Alter Chondrocyte Proliferation in Thanatophoric Dysplasia* , 1998, The Journal of Biological Chemistry.

[53]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[54]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[55]  D. Bar-Sagi,et al.  A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.